Saurabh Saha is an American biotech entrepreneur. ^[1]

Education

Saha received his undergraduate degree in biology from the California Institute of Technology. ^[2] He also attended both Harvard Business School and Oxford University. ^[3] Saha trained under Bert Vogelstein during his studies at the Johns Hopkins School of Medicine, ^[4] where he received both an MD and a PhD in cancer genetics. ^[5]

Career

After finishing graduate school, Saha joined the management consulting firm McKinsey & Company in their Pharmaceuticals and Medical Products Practice in New York City. ^[6] In 2005, he became the Director of the New Indications Discovery Unit at the Novartis Institutes for BioMedical Research based in Cambridge, Massachusetts. ^[5] Between 2008 and 2015, Saha served as the President of BioMed Valley Discoveries ^{[7] [3]} Saha serves as a venture partner for the life sciences venture capital firm, Atlas Venture and also served as the Chief Medical Officer for its portfolio company, Synlogic. ^[8]

In 2016, Saha was appointed as President and CEO of Delinia, a biotech company focused on developing novel therapies for the treatment of cancer and autoimmune diseases such as lupus, inflammatory bowel disease, rheumatoid arthritis and others. ^{[9] [10] [11]}

Saha has published in periodicals where he and his colleagues reported translational research and development discoveries in cancer research. ^{[12] [13] [14] [15] [16] [17] [18]} He is also on the editorial boards of the American Journal of Clinical Oncology, ^[19] Journal of Translational Medicine, ^[20] and Cancer Biology & Therapy. ^[21]

References